The study aimed to assess the prevalence of anemia among patients with various stages of chronic kidney disease (CKD) in Saudi Arabia, using data from 11 different medical centers.
The cohort included 250 patients, with anemia prevalence rates escalating from 42% in stage 1 to 82% in stage 5 for hemoglobin levels below 12 g/dL, indicating a significant issue across all stages.
The findings suggest a high demand for erythropoietin treatment among these patients, but the anticipated dosage may be manageable due to the availability of effective long-acting treatments, making it less costly and more effective for patient care.